Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral furosemide Clear all
Not listed Not applicable Interventional

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

NCT00924014
View directory record Official record
Conditions
Heart Failure
Interventions
Conivaptan, Furosemide, Conivaptan and furosemide
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Not applicable Interventional

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

NCT00240019
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Addition of furosemide 20 mg oral bid to baseline regimen
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Santa Clara, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2006 · Synced Oct 21, 2026, 10:40 AM EDT
Not listed Phase 2Phase 3 Interventional

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

NCT01721655
View directory record Official record
Conditions
Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 4 Interventional Results available

Protocolized Diuretic Strategy in Cardiorenal Failure

NCT01921829
View directory record Official record
Conditions
Cardiac Failure, Renal Failure, Kidney Failure
Interventions
Protocolized Diuretic Strategy
Drug
Lead sponsor
Kelly V. Liang, MD
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 21, 2026, 10:40 AM EDT
Not yet recruiting Phase 3 Interventional

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

NCT07018297
View directory record Official record
Conditions
Heart Failure, Acute Decompensated Heart Failure
Interventions
Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional Results available

Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial

NCT03259165
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
Interventions
Nitrates, Loop Diuretics
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331
View directory record Official record
Conditions
Heart Failure, Dyspnea
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Aurora, Colorado • Atlanta, Georgia • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 21, 2026, 10:40 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional

AiDing Diuresis wIth Tolvaptan (ADD-IT)

NCT02646540
View directory record Official record
Conditions
Cardiomyopathy, Congestive Heart Failure
Interventions
Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

NCT04622709
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Furosemide (loop diuretic) Tablets
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure

NCT05093621
View directory record Official record
Conditions
Heart Failure
Interventions
Furosemide, Torsemide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 4 Interventional Results available

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

NCT03746002
View directory record Official record
Conditions
Fluid Overload, Heart Failure Acute
Interventions
Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 4 Interventional Results available

Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

NCT00904488
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Addition of oral Metolazone, Furosemide dose escalation
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Furosemide for Accelerated Recovery of Blood Pressure Postpartum

NCT03556761
View directory record Official record
Conditions
Hypertension, Pregnancy-Induced
Interventions
Oral furosemide, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

NCT01901809
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Furosemide, Dopamine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional Results available

Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

NCT03170219
View directory record Official record
Conditions
Acute Heart Failure, Decompensated Heart Failure
Interventions
subcutaneous furosemide and sc2wear device
Combination Product
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Lasix for the Prevention of De Novo Postpartum Hypertension

NCT04752475
View directory record Official record
Conditions
Postpartum Pregnancy-Induced Hypertension, Postpartum Preeclampsia, Hypertension, Pregnancy-Induced, Hypertension
Interventions
Furosemide, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

NCT00575484
View directory record Official record
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
Drug
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 21, 2026, 10:40 AM EDT